Literature DB >> 31214962

The clinical and prognostic value of miR-9 gene expression in Tunisian patients with bladder cancer.

Lucia Cicchillitti1, Rahma Said2, Nouha Setti Boubaker2,3, Aymone Gurtner3, Haroun Ayed4, Ahlem Blel5, Omar Karray4, Mohamed Ali Essid4, Maroua Gharbi4, Abderrazek Bouzouita4, Soumaya Rammeh Rommeni5, Mohamed Chebil4, Giulia Piaggio6, Slah Ouerhani7.   

Abstract

There is a major need for the identification of biomarkers, which are able to guide personalized therapy for bladder cancer, in particular after resection of the primary tumor. Specifically, miR-9 upregulation has been preliminarily associated with a more aggressive phenotype of bladder cancer, namely muscle-invasive bladder cancer (MIBC) or high-grade non-muscle-invasive bladder cancer (HG NMIBC). In order to explore the potential utility of miR-9 as a biomarker in bladder cancer, we have investigated its expression pattern in a sample of Tunisian patients who have undergone primary resection. This is a retrospective study performed on BCa samples from 90 patients (44 specimens of HG NMIBC, 23 specimens of LG NMIBC, and 23 specimens of MIBC). Ten samples from the non-tumoral zone of cystectomy specimens were used as controls. For each specimen, we measured miR-9 expression and correlated it with the clinical characteristics of the patients. Overall, miR-9 was overexpressed in MIBC compared to NMIBC specimens (median fold change [FC]: - 8.89 vs 1.41, p = 0.001). Similarly, miR-9 expression was significantly different in LG NMIBC, HG NMIBC and MIBC subgroups (median FC: 0.68, 2.14 and 8.89, respectively; p = 0.001). ROC analysis showed that miR-9 expression pattern could be used as potential biomarker for distinguishing NMIBC subgroups: indeed miR-9 expression is relatively low in LG NMIBC and high in HG NMIBC. The thresholds are estimated at 0.063 and 21.597, respectively. Moreover, miR-9 was associated with a higher risk of progression. This study suggests the clinical value of miR-9 as a prognostic factor in bladder cancer after tumor resection. Should the prognostic ability of miR-9 be confirmed in larger studies, also on different ethnic groups, it would be useful to investigate whether urine sampling-which is easier to perform, less invasive and less costly-can provide the same results as analysis on surgical specimens.

Entities:  

Keywords:  Biomarkers; Epigenetic variation; Neoplasms; Prognosis; Urinary bladder; miRN

Mesh:

Substances:

Year:  2019        PMID: 31214962     DOI: 10.1007/s11033-019-04920-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  22 in total

1.  miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer.

Authors:  Haifeng Wang; Wei Zhang; Yigang Zuo; Mingxia Ding; Changxing Ke; Ruping Yan; Hui Zhan; Jingyu Liu; Jiansong Wang
Journal:  Tumour Biol       Date:  2015-07-07

Review 2.  microRNA expression profiles as decision-making biomarkers in the management of bladder cancer.

Authors:  Sharon Amir; Nicola J Mabjeesh
Journal:  Histol Histopathol       Date:  2016-09-02       Impact factor: 2.303

3.  Investigation of key miRNAs and target genes in bladder cancer using miRNA profiling and bioinformatic tools.

Authors:  Kemal Murat Canturk; Muhsin Ozdemir; Cavit Can; Setenay Öner; Ramazan Emre; Huseyin Aslan; Oguz Cilingir; Evrim Ciftci; Fatih Mehmet Celayir; Ozgur Aldemir; Mustafa Özen; Sevilhan Artan
Journal:  Mol Biol Rep       Date:  2014-09-05       Impact factor: 2.316

Review 4.  mRNA, microRNA and lncRNA as novel bladder tumor markers.

Authors:  Edyta Wieczorek; Edyta Reszka
Journal:  Clin Chim Acta       Date:  2017-12-07       Impact factor: 3.786

5.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

Authors:  Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096

Review 6.  The translational potential of microRNAs as biofluid markers of urological tumours.

Authors:  Annika Fendler; Carsten Stephan; George M Yousef; Glen Kristiansen; Klaus Jung
Journal:  Nat Rev Urol       Date:  2016-11-02       Impact factor: 14.432

7.  Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer.

Authors:  Takashi Shimizu; Hiromu Suzuki; Masanori Nojima; Hiroshi Kitamura; Eiichiro Yamamoto; Reo Maruyama; Masami Ashida; Tomo Hatahira; Masahiro Kai; Naoya Masumori; Takashi Tokino; Kohzoh Imai; Taiji Tsukamoto; Minoru Toyota
Journal:  Eur Urol       Date:  2012-11-23       Impact factor: 20.096

Review 8.  MicroRNAs as biomarkers associated with bladder cancer.

Authors:  Amene Homami; Farideh Ghazi
Journal:  Med J Islam Repub Iran       Date:  2016-12-29

Review 9.  Approved checkpoint inhibitors in bladder cancer: which drug should be used when?

Authors:  Pooja Ghatalia; Matthew Zibelman; Daniel M Geynisman; Elizabeth Plimack
Journal:  Ther Adv Med Oncol       Date:  2018-07-30       Impact factor: 8.168

Review 10.  Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring.

Authors:  Iris Lodewijk; Marta Dueñas; Carolina Rubio; Ester Munera-Maravilla; Cristina Segovia; Alejandra Bernardini; Alicia Teijeira; Jesús M Paramio; Cristian Suárez-Cabrera
Journal:  Int J Mol Sci       Date:  2018-08-24       Impact factor: 5.923

View more
  1 in total

1.  Chrysophanol suppresses growth and metastasis of T cell acute lymphoblastic leukemia via miR-9/PD-L1 axis.

Authors:  Junjie Yin; Qingsong Yin; Bo Liang; Ruihua Mi; Hao Ai; Lin Chen; Xudong Wei
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-14       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.